AURKB and hepatocellular carcinoma: We have demonstrated, for the first time, that Artemisinin-treated HCC cells displayed marked suppression of FoxM1 (Figures 2A–H) level and transcriptional activity (Figures 2I–L and Supplementary Figure 3), which culminates in decreased expression of its transcriptional targets, including Plk1, CyclinB1, Skp2 and Aurora B Kinase, among others.